Perinatal Ethanol Exposure Induces Astrogliosis and Decreases GRP55/PEA-Mediated Neuroprotection in Hippocampal Astrocytes of the 3×Tg Alzheimer’s Animal Model

Prenatal ethanol exposure (PEE) alters fetal brain development, potentially increasing the risk of neurodegenerative diseases such as Alzheimer’s disease (AD) later in life. Although glial activation is implicated in AD pathology via cannabinoid and neuroinflammatory signaling, its potential response to PEE in the developing brain and its contribution to AD pathogenesis remain unknown. Using 3×Tg-AD offspring of both sexes born to mothers with PEE, we analyzed astrogliosis, inflammatory markers, and key components of cannabinoid and Ca2+ signaling in primary cultures of hippocampal astrocytes, elements whose dysfunction contributes to neurodegeneration. Our results indicated that PEE increased astrogliosis/inflammatory response (significant elevation of Gfap and Tnfα expression) in hippocampal astrocytes at birth. This neuroinflammation was significantly associated with lower expression of cannabinoid receptors (Cnr1 and Gpr55), and decreased concentrations of the anti-inflammatory lipid PEA in the culture medium, probably due to a deregulated endocannabinoid enzymatic machinery (NAPE-PLD/FAAH ratio). This research provides insights into GRP55/PEA-mediated signaling as a potential hippocampal astrocytic mechanism influenced by maternal ethanol exposure, which may contribute to neurobiological changes associated with increased vulnerability to AD-related pathology.

• Publication year

  2025

• Venue

  International Journal of Molecular Sciences

• Publication date

  2025-11-01

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.3390/ijms262211154PMID 41303637PMCID 12652644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Palmitoylethanolamide: A Multifunctional Molecule for Neuroprotection, Chronic Pain, and Immune Modulation

  2025cited by this paper
• The Role of Endocannabinoids in Physiological Processes and Disease Pathology: A Comprehensive Review

  2025cited by this paper
• Upregulation of Na/H Exchanger in Astrogliosis and Early Alzheimer’s Disease Pathogenesis

  2024cited by this paper
• The Endocannabinoid System in Alzheimer's Disease: A Network Meta‐Analysis

  2024cited by this paper
• Sex-Dependent Altered Expression of Cannabinoid Signaling in Hippocampal Astrocytes of the Triple Transgenic Mouse Model of Alzheimer’s Disease: Implications for Controlling Astroglial Activity

  2023influential reference
• The Expression of the Endocannabinoid Receptors CB2 and GPR55 Is Highly Increased during the Progression of Alzheimer’s Disease in AppNL-G-F Knock-In Mice

  2023cited by this paper
• Alcohol as a Modifiable Risk Factor for Alzheimer’s Disease—Evidence from Experimental Studies

  2023cited by this paper
• Epigenetics in fetal alcohol spectrum disorder.

  2023cited by this paper
• Anxiety associated with palatable food withdrawal is reversed by the selective FAAH inhibitor PF-3845: A regional analysis of the contribution of endocannabinoid signaling machinery.

  2023cited by this paper
• Sex-related differences among individuals assessed for fetal alcohol spectrum disorder in Canada.

  2023cited by this paper
• Administration of Linoleoylethanolamide Reduced Weight Gain, Dyslipidemia, and Inflammation Associated with High-Fat-Diet-Induced Obesity

  2023cited by this paper
• Altered Epigenetic Marks and Gene Expression in Fetal Brain, and Postnatal Behavioural Disorders, Following Prenatal Exposure of Ogg1 Knockout Mice to Saline or Ethanol

  2023cited by this paper
• Prenatal and adolescent alcohol exposure, neuroinflammation, and Alzheimer’s disease: a network meta analysis approach

  2023cited by this paper
• Endocannabinoid signaling in astrocytes

  2022cited by this paper
• Review of Alzheimer’s disease drugs and their relationship with neuron-glia interaction

  2022cited by this paper
• Therapeutic effect of palmitoylethanolamide in cognitive decline: A systematic review and preliminary meta-analysis of preclinical and clinical evidence

  2022cited by this paper
• Activation of GPR55 attenuates cognitive impairment, oxidative stress, neuroinflammation, and synaptic dysfunction in a streptozotocin-induced Alzheimer's mouse model.

  2022cited by this paper
• Ethanol Gestational Exposure Impairs Vascular Development and Endothelial Potential to Control BBB-Associated Astrocyte Function in the Developing Cerebral Cortex

  2021cited by this paper
• Modifiable, Non-Modifiable, and Clinical Factors Associated with Progression of Alzheimer’s Disease

  2021cited by this paper
• Prenatal ethanol exposure impairs the formation of radial glial fibers and promotes the transformation of GFAPδ-positive radial glial cells into astrocytes

  2021cited by this paper
• Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence

  2021cited by this paper
• Activation of GPR55 attenuates cognitive impairment and neurotoxicity in a mouse model of Alzheimer's disease induced by Aβ1-42 through inhibiting RhoA/ROCK2 pathway.

  2021cited by this paper
• Sex- and OGG1-dependent reversal of in utero ethanol-initiated changes in postnatal behaviour by neonatal treatment with the histone deacetylase inhibitor trichostatin A (TSA) in oxoguanine glycosylase 1 (Ogg1) knockout mice.

  2021cited by this paper
• Imbalance of Endocannabinoid/Lysophosphatidylinositol Receptors Marks the Severity of Alzheimer’s Disease in a Preclinical Model: A Therapeutic Opportunity

  2020cited by this paper
• Unraveling the molecular mechanisms involved in alcohol intake and withdrawal in adolescent mice exposed to alcohol during early life stages.

  2020cited by this paper
• Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease.

  2020cited by this paper
• Endocannabinoid system alterations in Alzheimer's disease: a systematic review of human studies.

  2020cited by this paper
• The Basal Pharmacology of Palmitoylethanolamide

  2020cited by this paper
• Modulation of the Cannabinoid System: A New Perspective for the Treatment of the Alzheimer’s Disease

  2019cited by this paper
• Cannabinoids and the expanded endocannabinoid system in neurological disorders

  2019cited by this paper
• Adolescent ethanol intake alters cannabinoid type‐1 receptor localization in astrocytes of the adult mouse hippocampus

  2019cited by this paper
• Palmitoylethanolamide Dampens Reactive Astrogliosis and Improves Neuronal Trophic Support in a Triple Transgenic Model of Alzheimer's Disease: In Vitro and In Vivo Evidence

  2018cited by this paper
• Brain endocannabinoid signaling exhibits remarkable complexity.

  2018cited by this paper
• Palmitoylethanolamide Ameliorates Hippocampal Damage and Behavioral Dysfunction After Perinatal Asphyxia in the Immature Rat Brain

  2018cited by this paper
• The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations

  2017cited by this paper
• Alcohol and basal ganglia circuitry: Animal models

  2017cited by this paper
• Beneficial Effects of Co‐Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of Autism and in a Case Report of Autism

  2017cited by this paper
• CB2 Cannabinoid Receptor As Potential Target against Alzheimer's Disease

  2016cited by this paper
• Astroglial type-1 cannabinoid receptor (CB1): A new player in the tripartite synapse.

  2016cited by this paper
• The Association Between Alcohol Use and the Progression of Alzheimer's Disease.

  2016cited by this paper
• Ethanol-Induced Neurodegeneration and Glial Activation in the Developing Brain

  2016cited by this paper
• WIN 55,212-2, Agonist of Cannabinoid Receptors, Prevents Amyloid β1-42 Effects on Astrocytes in Primary Culture

  2015cited by this paper
• Distribution of the Endocannabinoid System in the Central Nervous System.

  2015cited by this paper
• Rising stars: Modulation of brain functions by astroglial type‐1 cannabinoid receptors

  2015cited by this paper
• Cocaine-Induced Behavioral Sensitization Is Associated With Changes in the Expression of Endocannabinoid and Glutamatergic Signaling Systems in the Mouse Prefrontal Cortex

  2014cited by this paper
• Analysis of ECs and related compounds in plasma: artifactual isomerization and ex vivo enzymatic generation of 2-MGs[S]

  2014cited by this paper
• CB2 receptor and amyloid pathology in frontal cortex of Alzheimer's disease patients.

  2013cited by this paper
• Leptin regulates glutamate and glucose transporters in hypothalamic astrocytes.

  2012cited by this paper

• No citing papers are available for this paper.